Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

ImmunityBio (IBRX) Other Gross PP&E Adjustments (2016 - 2025)

ImmunityBio (IBRX) has disclosed Other Gross PP&E Adjustments for 12 consecutive years, with $177.0 million as the latest value for Q4 2025.

  • Quarterly Other Gross PP&E Adjustments fell 3.04% to $177.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $177.0 million through Dec 2025, down 3.04% year-over-year, with the annual reading at $177.0 million for FY2025, 3.04% down from the prior year.
  • Other Gross PP&E Adjustments for Q4 2025 was $177.0 million at ImmunityBio, down from $205.1 million in the prior quarter.
  • The five-year high for Other Gross PP&E Adjustments was $205.1 million in Q3 2025, with the low at $76.5 million in Q4 2021.
  • Average Other Gross PP&E Adjustments over 5 years is $161.7 million, with a median of $179.4 million recorded in 2023.
  • The sharpest move saw Other Gross PP&E Adjustments decreased 7.77% in 2021, then surged 91.06% in 2022.
  • Over 5 years, Other Gross PP&E Adjustments stood at $76.5 million in 2021, then skyrocketed by 91.06% to $146.2 million in 2022, then grew by 17.21% to $171.4 million in 2023, then grew by 6.51% to $182.5 million in 2024, then dropped by 3.04% to $177.0 million in 2025.
  • According to Business Quant data, Other Gross PP&E Adjustments over the past three periods came in at $177.0 million, $205.1 million, and $203.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.